Cantor Fitzgerald Predicts BEAM FY2025 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Beam Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski anticipates that the company will earn ($3.48) per share for the year. Cantor Fitzgerald currently has a “Hold” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.64) per share.

Several other research firms also recently issued reports on BEAM. Scotiabank assumed coverage on shares of Beam Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $24.00 price objective for the company. Leerink Partnrs upgraded Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Wedbush reiterated an “outperform” rating and issued a $57.00 price objective on shares of Beam Therapeutics in a research note on Monday, January 13th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Beam Therapeutics in a report on Monday, December 9th. Finally, Royal Bank of Canada cut their target price on shares of Beam Therapeutics from $27.00 to $24.00 and set a “sector perform” rating on the stock in a report on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $47.67.

Beam Therapeutics Price Performance

NASDAQ BEAM opened at $26.29 on Thursday. The firm’s fifty day moving average price is $26.31 and its 200 day moving average price is $25.73. Beam Therapeutics has a 12 month low of $20.84 and a 12 month high of $49.50. The company has a market capitalization of $2.18 billion, a price-to-earnings ratio of -14.94 and a beta of 1.92.

Beam Therapeutics (NASDAQ:BEAM) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.01). Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The business had revenue of $14.30 million during the quarter, compared to analyst estimates of $14.52 million. During the same period last year, the company earned ($1.22) earnings per share. The business’s revenue for the quarter was down 16.9% compared to the same quarter last year.

Institutional Investors Weigh In On Beam Therapeutics

Institutional investors have recently made changes to their positions in the stock. Blue Trust Inc. lifted its stake in shares of Beam Therapeutics by 84.0% in the third quarter. Blue Trust Inc. now owns 3,135 shares of the company’s stock valued at $73,000 after purchasing an additional 1,431 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Beam Therapeutics by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,981 shares of the company’s stock valued at $75,000 after buying an additional 524 shares in the last quarter. Quarry LP increased its holdings in Beam Therapeutics by 350.0% in the second quarter. Quarry LP now owns 3,600 shares of the company’s stock valued at $84,000 after buying an additional 2,800 shares in the last quarter. Arcadia Investment Management Corp MI acquired a new stake in shares of Beam Therapeutics during the 3rd quarter valued at approximately $98,000. Finally, KBC Group NV boosted its stake in shares of Beam Therapeutics by 103.2% during the 4th quarter. KBC Group NV now owns 4,143 shares of the company’s stock worth $103,000 after acquiring an additional 2,104 shares in the last quarter. 99.68% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, President Giuseppe Ciaramella sold 51,110 shares of Beam Therapeutics stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $26.36, for a total value of $1,347,259.60. Following the sale, the president now directly owns 109,150 shares in the company, valued at $2,877,194. The trade was a 31.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Christine Bellon sold 1,241 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $24.68, for a total value of $30,627.88. Following the transaction, the insider now directly owns 102,968 shares in the company, valued at $2,541,250.24. This represents a 1.19 % decrease in their position. The disclosure for this sale can be found here. 4.20% of the stock is owned by insiders.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.